WFS
BMRN icon

Widmann Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Widmann Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10
Closed – – 125
2021
Q4 		$0 Buy
+10
New +$825 ﹤0.01% 455

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Widmann Financial Services's BMRN Position: Q1 2022 in Review

Widmann Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 10 shares.

Widmann Financial Services first reported a position in BMRN in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Widmann Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Widmann Financial Services sold 10 BioMarin Pharmaceuticals shares in Q1 2022.
  • Widmann Financial Services first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Widmann Financial Services's BioMarin Pharmaceuticals position peaked at $0 in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Widmann Financial Services's 13F filing for Q1 2022, filed 4 May 2022.